Target $10.00 in 2011Target $10.00 in 2011
Profile:Allos Therapeutics is a biopharmaceutical company focused on developingand commercializing innovative small-molecule drugs for the treatmentof cancer. The company's Folotyn (pralatrexate) is designed to treatT-cell lymphoma.
Share Price: $4.35(Dec. 17)
2010 Stock Performance: -34%
Analyst Consensus:Seven analysts say investors should buy shares of Allos Therapeutics.Three other analysts recommend that investors hold shares. No researcherhas a "sell" rating on Allos.
Bullish Case: In a Dec. 13 research note, ThinkEquityanalyst Brian Skorney said the firm has a "buy" rating and a $10 pricetarget on Allos, noting several new clinical analyses of Folotyn.
"New data in T-cell malignancies show compelling efficacycompared to potential competitors and provides additional rationale foroncologists to adopt Folotyn as an important therapy for patients,"Skorney wrote.